The present invention relates to novel mutants of bone morphogenetic
proteins (BMPs) useful as inhibitors of heterotopic ossification.
Specifically, the present invention related to novel mutants containing
only the entire region involved in the formation of finger 2 including
the wrist epitope of a BMP with a specific cysteine residue or specific
cysteine residues replaced by a different amino acid. The present
invention also relates to pharmaceutical compositions containing these
mutants and to methods for using the mutants and pharmaceutical
compositions in therapy.